Dyslipidemia is a potentially modifiable cardiovascular risk factor. Whereas the recommendations for the treatment target of dyslipidemia in the general population are being more and more rigorous, the 2013 Kidney Disease: Improving Global Outcomes clinical practice guideline for lipid management in chronic kidney disease (CKD) presented a relatively conservative approach with respect to the indication of lipid lowering therapy and therapeutic monitoring among the patients with CKD. This may be largely attributed to the lack of high-quality evidence derived from CKD population, among whom the overall feature of dyslipidemia is considerably distinctive to that of general population. In this review article, we cover the characteristic features of dyslipidemia and impact of dyslipidemia on cardiovascular outcomes in patients with CKD. We also review the current evidence on lipid lowering therapy to modify the risk of cardiovascular events in this population. We finally discuss the association between dyslipidemia and CKD progression and the potential strategy to delay the progression of CKD in relation to lipid lowering therapy.
Citations
Citations to this article as recorded by
Impact of remnant cholesterol on short-term and long-term prognosis in patients with prediabetes or diabetes undergoing coronary artery bypass grafting: a large-scale cohort study Zhongchen Li, Chunyu Yu, Heng Zhang, Runze Chen, Yan Zhao, Zhe Zheng Cardiovascular Diabetology.2025;[Epub] CrossRef
Effects of Tocotrienol on Cardiovascular Risk Markers in Patients With Chronic Kidney Disease: A Randomized Controlled Trial Liana Trugilho, Lívia Alvarenga, Ludmila Cardozo, Bruna Paiva, Jessyca Brito, Isis Barboza, Jonatas Almeida, Juliana dos Anjos, Pramod Khosla, Marcelo Ribeiro-Alves, Denise Mafra, Eric Gumpricht Journal of Nutrition and Metabolism.2025;[Epub] CrossRef
The Impact of Glomerular Disease on Dyslipidemia in Pediatric Patients Treated with Dialysis Edward Zitnik, Elani Streja, Marciana Laster Nutrients.2025; 17(3): 459. CrossRef
Statin Therapy and Lipid Indices in Chronic Kidney Disease: A Systematic
Review and Meta-analysis of Randomized Control Trials Jafar Karami, Bahman Razi, Danyal Imani, Saeed Aslani, Mahdi Pakjoo, Mahdieh Fasihi, Keyhan Mohammadi, Amirhossein Sahebkar Current Pharmaceutical Design.2024; 30(5): 362. CrossRef
Lipoprotein glomerulopathy with markedly increased arterial stiffness successfully treated with a combination of fenofibrate and losartan: a case report Junichiro Kato, Hideo Okonogi, Go Kanzaki, Haruki Katsumata, Yasuyuki Nakada, Makoto Sagasaki, Kazumasa Komine, Kenji Ito, Takao Saito, Akira Matsunaga, Koh Tokutou, Kazuho Honda, Nobuo Tsuboi, Takashi Yokoo BMC Nephrology.2024;[Epub] CrossRef
Atherogenic index of plasma: a new indicator for assessing the short-term mortality of patients with acute decompensated heart failure Meng Yu, Hongyi Yang, Maobin Kuang, Jiajun Qiu, Changhui Yu, Guobo Xie, Guotai Sheng, Yang Zou Frontiers in Endocrinology.2024;[Epub] CrossRef
Association between lipid accumulation product index and chronic kidney disease: A systematic review and meta-analysis Feixiang Wu, Chenmin Cui, Junping Wu, Yunqing Wang Experimental and Therapeutic Medicine.2024;[Epub] CrossRef
Potential impact of sodium glucose co-transporter (SGLT2) inhibitors on cholesterol fractions in stage 3 chronic kidney disease Rabab Mahmoud Ahmed, Nehal Kamal Rakha, Ahmed Yousry, Amin Roshdy Soliman The Egyptian Journal of Internal Medicine.2024;[Epub] CrossRef
Pulmonary Hypertension in Hemodialysis Patients and Its Determinants: A Hospital Based Cross-Sectional Study Qingfei Yu, Qin Zhang International Journal of General Medicine.2024; Volume 17: 3919. CrossRef
Relationship Between Serum Uromodulin as a Marker of Kidney Damage and Metabolic Status in Patients with Chronic Kidney Disease of Non-Diabetic Etiology Radmila Žeravica, Branislava Ilinčić, Dragan Burić, Ana Jakovljević, Veljko Crnobrnja, Dalibor Ilić, Marija Vukmirović Papuga International Journal of Molecular Sciences.2024; 25(20): 11159. CrossRef
Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes Natalia Stepanova Biomedicines.2024; 12(10): 2377. CrossRef
Causal associations between kidney function and aortic valve stenosis: a bidirectional Mendelian randomization analysis Wanqian Pan, Le Zhou, Rui Han, Xiaojiao Du, Weixiang Chen, Tingbo Jiang Renal Failure.2024;[Epub] CrossRef
U-shaped association between dietary niacin intake and chronic kidney disease among US elderly: a nationwide cross-sectional study Zhouzhou Xie, Shansen Peng, Gejun Ou, Xiaoqi Zhou, Guihao Zhang, Huiming Jiang, Tianhui Zhang, Nanhui Chen Frontiers in Endocrinology.2024;[Epub] CrossRef
Association between dried fruit intake and kidney function: research from univariate and multivariate Mendelian randomized studies Yuhang Gao, Xinghai Yue, Wanchao Zhao, Fang Yuan Frontiers in Nutrition.2024;[Epub] CrossRef
The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease Alfredo Caturano, Raffaele Galiero, Maria Rocco, Giuseppina Tagliaferri, Alessia Piacevole, Davide Nilo, Giovanni Di Lorenzo, Celestino Sardu, Vincenzo Russo, Erica Vetrano, Marcellino Monda, Raffaele Marfella, Luca Rinaldi, Ferdinando Carlo Sasso Biomolecules.2024; 14(11): 1393. CrossRef
Association between the EHBP1 SNPs and dyslipidemia in the end-stage renal disease patients with dialysis in Chinese Han population Yan-Fei Lai, Zhong-E Liang, Chun-Xiang Wu, Min Zhang, Zong-Hu Shi, Xiao-Yan Meng, Chun-Xiao Liu Lipids in Health and Disease.2024;[Epub] CrossRef